Lumora review

The public descriptions present two routes. The homepage describes a free assessment without a card, then provider review and recommended-plan pricing. The medication pages say to select a supply option before secure onboarding and promise option pricing before checkout. The rendered options show oral/sublingual semaglutide at $295 and tirzepatide at $345. Tirzepatide also shows $590 for two months and $680 for three months. The base cards do not specify duration; none establishes the injectable or complete recurring treatment bill. Those prices are visible before entering an assessment. Before committing, obtain an itemized total for the consultation, medication, required labs and follow-up. Check the supply length, amount collected immediately, renewal frequency and next charge. A starting option would still need to match the clinician's actual prescription. If the recommended concentration, quantity or route changes after review, ask for the revised total before authorizing payment rather than assuming the first offer remains applicable.

The semaglutide page lists five subcutaneous concentration tiers, while tirzepatide lists six. Both describe B12 or glycine variants and separate sublingual forms. Those injection descriptions do not establish injection prices or a personal dosing schedule. The publicly priced oral/sublingual supply options should not be substituted for injectable treatment. Concentration tells you about the preparation; it does not independently establish how much you should take, how long a supply lasts or what you will pay. The different administration routes also should not be treated as clinically interchangeable on the strength of a shared ingredient name. Ask your prescriber to identify the exact formulation, prescribed amount, instructions and reason for any added ingredient. Confirm that the written offer matches that prescription. Lumora's weight-loss percentages and ingredient-benefit language do not independently demonstrate the outcomes of the specific compounded formulation you might receive, and this review has no firsthand treatment experience to resolve those claims.

Yes, its GLP-1 pages explicitly describe baseline testing. Semaglutide requires metabolic labs, and tirzepatide describes typical HbA1c, lipids, kidney-function and thyroid testing, with further tests depending on medical history. That is a meaningful care requirement, but the payment side is less definite. The public promise to show laboratory costs before commitment does not establish that Lumora funds every panel, blood draw or repeat test. Ask which tests your clinician requires, whether recent outside results can be accepted, where specimens are collected and who bills you. For ongoing care, establish when another panel might be needed and whether its charge falls inside the quoted plan. Budgeting solely for medication could leave out a required step. Conversely, the lack of a universal lab allowance is not evidence that testing is optional or that every patient receives the same bill.

Lumora's March 2026 privacy policy and footer identify Blue Skies MD LLC DBA Lumora MD. The June 2026 terms open with Blue Skies LLC dba Lumora MD, while their contact section uses Blue Skies MD LLC. Those are the disclosed names; the variation should be clarified on your agreement rather than silently treated as identical. The terms describe a coordinating platform, with independent clinicians responsible for treatment. Its providers page attributes care to Arora Health & Aesthetics and names Sean Arora and Shannon Arora in leadership descriptions. Those biographies are merchant disclosures, not a fresh credential check or your personal assignment. Separately, the terms describe pharmacy-network fulfillment and requesting a pharmacy of choice. No particular dispensing facility is established for your order. Ask for both the treating clinician and dispensing pharmacy; shared clinical branding alone does not establish common ownership with another storefront.

The June 2026 terms permit cancellation through account settings or support email before the next billing date. They do not provide a universal numeric advance-notice interval, so confirm the next bill and retain the cancellation confirmation. A clinical instruction to pause or stop treatment is separate from ending billing. Processed orders are generally nonrefundable, with possible exceptions for damage, transit loss or unavailable treatment. If prescribed treatment becomes unavailable, an unshipped prepaid portion may qualify for a prorated refund; approved refunds can take up to 30 days. Alternative treatment or platform credit may also be offered. These conditions are narrower than an unrestricted cash refund. The weight-management page's inability-to-prescribe language is subject to checkout terms, so ask which charges are recoverable after denial and which order stage changes your rights before agreeing to pay.

The advertised 50-state network is qualified by state-specific medications, protocols and laboratory requirements. Eligibility also depends on age, physical location and a provider licensed for that location; the terms generally require adults, with some services reserved for people 21 or older. Confirm access for the actual treatment rather than relying only on national branding. Help is advertised by weekday telephone, support email and account-based provider messages. Typical review and email times are expectations, not guaranteed continuous clinical availability. For delivery, ask which pharmacy supplies the order, when required labs and review must be complete, what shipping costs and how delays or temperature concerns are handled. Also obtain the included supplies list and administration instructions. Neither a generic fulfillment statement nor an injection listing verifies a complete kit, free shipping or a promised arrival date.